Valaciclovir:development, clinical utility and potential

Bibliography

• WHITLEY RJ, GNANN JW: Acyclovir: a decade later. New Engl. J. Med. (1992) 327:782–789.
   PubMed Web of Science ®Google Scholar
• ELION GB: The biochemistry and mechanism of action of acyclovir. J. Antimicrob. Chemother. (1983) 12:9–17.
   PubMed Web of Science ®Google Scholar
• TILSON FITI, ENGLE CR, ANDREWS EB: Safety of acyclovir: a summary of the first 10 years experience. J. Med. Vim]. (1993) 41 (Suppl. 1)67–73.
   Google Scholar
• MINDEL A, FAHERTY A, CARNEY 0 et al: Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet (1988) 1:926–928.
   PubMed Web of Science ®Google Scholar
• GOLDBERG LH, KAUFMAN R, KURTZ TO et al: Long-term suppression of recurrent genital herpes with acyclovir. A five year bench mark. Arch. Dermatol (1993) 129:582–587.
   PubMedGoogle Scholar
• GLUCKMAN E, LOTSBERG J, DEVERGIE A et al.: Prophy-laxis of herpes infections after bone marrow transplan-tation by oral acyclovir. Lancet (1983) 2:706–708.
   PubMed Web of Science ®Google Scholar
• PETTERSSON E, HOVI T, AHONEN J et al.: Prophylactic oral acyclovir after renal transplantation. Transplanta-tion (1985) 39:279–281.
   PubMed Web of Science ®Google Scholar
• EISEN SA, MILLER DK, WOODWARD RS et al.: The effect of prescribed daily dose frequency on patient medica-tion compliance. Arch. Intern. Med. (1990) 150:1881–1884.
   PubMed Web of Science ®Google Scholar
• KROON S (Ed.): Limiting the continued spread of genital herpes. Recommendations from the IHMF Management Strategies Workshop. PPS Europe Ltd., Worthing (1994).
   Google Scholar
• WALD A, ZEH J, BARNUM G et al.: Suppression of sub-clinical shedding of herpes simplex virus type 2 with acyclovir. Ann. Intern. Med. (1996) 124:8–15.
   PubMed Web of Science ®Google Scholar
• BRYSON Y, DILLON M, BERNSTEIN DI et al: Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J. Infect. Dis. (1993) 167:942–946.
   PubMed Web of Science ®Google Scholar
• KOUTSKY LA, ASHLEY R, HOLMES KK eta].: The frequency of unrecognised type 2 herpes simplex virus infection among women: implications for the control of genital herpes. Sex. Transm. Dis. (1990) 17:90–94.
   Google Scholar
• WOOD MJ (Ed.): How can the burden of zoster-associ-ated pain be reduced? Recommendations from the IHMF Management Strategies Workshop. PPS Europe Ltd., Worthing (1993).
   Google Scholar
• MCKENDRICK MW, CARE C, BURKE C eta].: Oral acyclovir in herpes zoster. j Antimicrob. Chemother. (1984) 14:661–665.
   PubMed Web of Science ®Google Scholar
• WOOD MJ, OGAN PH, MCKENDRICK MW et al: Efficacy of oral acyclovir treatment of acute herpes zoster. Am. J. Med. (1988) 85:79–83.
   PubMed Web of Science ®Google Scholar
• HUFF JC, BEAN B, BALFOUR HFI etal.: Therapy of herpes zoster with acyclovir. Am. J. Med. (1988) 85:84–89.
   Google Scholar
• MORTON P, THOMSON AN: Oral acyclovir in the treat-ment of herpes zoster in general practice. N. Z Med. J. (1989) 102:93–95.
   PubMed Web of Science ®Google Scholar
• WOOD MJ, KAY R, DWORKIN RH et al: Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster - a meta-analysis of placebo-controlled trials. Clin. Infect. Dis. (1996) 22:341–347.
   PubMed Web of Science ®Google Scholar
• BUHLES, WC, MASTRE BJ, TINKER AJ et al: Ganciclovirtreatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromis ed pa-tients. Rev. Infect. Dis. (1988) 10:495–506.
   PubMedGoogle Scholar
• JABS DA, ENGER C, BARTLETT JG: Cytomegalovirus ret-init is and acquired immunodeficiency syndrome. Arch. Ophthalmol (1989) 170:75–80.
   Google Scholar
• KATLAMA C, DOHIN E, CAUMES E eta].: Foscarnet induc-tion therapy for cytomegalovirus ntinitis in AIDS: comparison of twice-daily and three-times daily regi-mens. J. Acquir. Immune Defic. Syndr. (1992) 5:518–S24.
   Google Scholar
• JACOBSON MA, CAUSEY DM, POLSKY B et al: A dose-rang-ing study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in patients with AIDS. J. Infect. Dis. (1993) 168:444–448.
   PubMed Web of Science ®Google Scholar
• STANAT SC, TALARICO CL, SULLIVAN V et al: Evidence that the HCMV-encoded UL97 contributes to the phos-phorylation of acyclovir in infected cells. 17th Interna-tional Herpesvirus Workshop. Edinburgh (1992). Abstract.
   Google Scholar
• TALARICO CL, STANAT SC, BIRON KK: Evidence that HCMV-encoded UL97 contributes to the phospboryla-tion of acyclovir in HCMV-infected cells. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando (1994). Abstract H65.
   Google Scholar
• BALFOUR HH, CHACE BA, STAPLETON JT et al.: A random-ized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal a llografts. New Engl. J. Med. (1989) 320:1381–1387.
   PubMed Web of Science ®Google Scholar
• PRENTICE HG, GLUCKMAN E, POWLES RL et al: Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet (1994) 26:749–753.
   Google Scholar
• SACKS SL, ALRABIAH F: Novel herpes treatments: a review. Exp. Opin. Invest. Drugs (1996) 5:169–183.
   Google Scholar
• VERE HODGE RA: Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem. Chemother. (1993) 4:67–84.
   Web of Science ®Google Scholar
• BOYD MR, SAFRIN S, KERN ER: Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem. Chemother. (1993) 4:3–11.
   Web of Science ®Google Scholar
• KO RBA BE, BOYD MR: Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob. Agents Chemother. (1996) 40:1282–1284.
   PubMed Web of Science ®Google Scholar
• PUE MA, BENET LZ: Pharmacokinetics of famciclovir in man. Antiviral Chem. Chemother. (1993) 4:47–55.
   Web of Science ®Google Scholar
• HARNDEN MR, JARVEST RL, BOYD MR eta].: Prodrugs of the selective antiherpesvirus agent 944-hydroxy-3-(hy-droxymethyDbut-1-yliguanine (BRL 39123) with im-proved absorption properties. J. Med. Chem. (1989) 32:1738–1743.
   Google Scholar
• RABORN GW, FOR THE PENCICLOVIR TOPICAL COLLABO-RATIVE STUDY GROUP: Penciclovir cream for recurrent herpes simplex labialis: an effective new treatment. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1996). Abstract H81.
   Google Scholar
• WHITLEY RJ: Sorivudine: a potent inhibitor of varicella zoster virus replication. In: Antiviral Chemotherapy 4 - New Directions for Clinical Application and Research. Mills J, Volberding PA, Corey L (Eds.), Plenum Publishing Corpo-ration, New York (1996):41–47.
   Google Scholar
• EDITORIAL: Usevir pulled as deaths follow launch. Mar-ket Letter (October 25, 1993).
   Google Scholar
• WELLER S, BLUM MR, DOUCETTE M eta].:Pharmacoki- netics of the acyclovir prodrug valaciclovir after esca- la ting single- and multiple-dose administration to nor-mal volunteers. Clin. Pharmacol Ther. (1993) 54:595–605.
   Google Scholar
• BEAUCHAMP LM, ORR GF, DE MIRANDA T et al: Amino acid ester prodrugs of acyclovir. Antiviral Chem. Chemother. (1992) 3:157–164.
   Web of Science ®Google Scholar
• BEAUCHAMP LM, KRENITSKY TA: Acyclovir prodrugs: the road to valaciclovir. Drugs Future (1993) 18:619–628.
   Google Scholar
• SZCZECH GM: Preclinical development of antiviral drugs. Clin. Infect. Di. (1996) 22:355–360.
   PubMed Web of Science ®Google Scholar
• NUSINOFF-LEHRMAN S, SMILEY L, SZCZECH GM: Update on acyclovir prodrugs. Antiviral Chemother. (1993) 3:97–104.
   Google Scholar
• BURNETTE TC, DE MIRANDA P: Metabolic disposition of the acyclovir prodrug valacyclovir in the rat. Drug. Metab. aspos. (1994) 22:60–64.
   PubMed Web of Science ®Google Scholar
• DE MIRANDA P, BURNETTE TC: Metabolic fate and phar-macokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug. Metab. Dispos. (1994) 22:55–
   PubMed Web of Science ®Google Scholar
• SOUL-LAWTON J, SEABER E, ON N etal: Absolute bioavail-ability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother. (1995) 39:2759–2764.
   PubMed Web of Science ®Google Scholar
• ELION GB: Acyclovir: discovery, mechanism of action, and selectivity. J. Med. Virol. (1993) Suppl. 1:2–6.
   Google Scholar
• FYFE JA, KELLER PM, FURMAN PA etal.: Thymidinekinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl) gua-nine. J. Biol. Chem. (1978) 253:8721–8727.
   Google Scholar
• FURMAN PA, ST CLAIR MH, SPECTOR T: Acyclovir triphos-phate is a suicide inactivator ofthe herpes simplexvirus DNA polymerase. 1 Biol. Chem. (1984) 259:9575–9579.
   Google Scholar
• ERTL P, SNOWDEN W, LOWE D eta].: A comparative study of the in vitro a nd in vivo antiviral activities of acyclovir and penciclovir. Antimicrob. Agents Chemother. (1995) 6:89–97.
   Google Scholar
• REARDON JE, SPECTOR T: Herpes simplex virus type 1 DNA polymerase: mechanism of inhibition by acyclovir triphosphate. J Biol. Chem. (1989) 264:7405–7411.
   PubMed Web of Science ®Google Scholar
• FURMAN PA, DE MIRANDA P, ST CLAIR MH et al.: Metabo-lism of acyclovir in virus infected and uninfected cells. Antimicrob. Agents Chemother. (1981) 20:518–524.
   Google Scholar
• COLLINS P, NIXON ELLIS M: Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. Med. Virol (1993) Suppl. 1:58–66.
   Google Scholar
• SNOECK R, ANDREI G, DE CLERCQ E: Chemotherapy of varicella zoster virus infections. Intl Antimicrob. Agents (1994) 4:211–226.
   PubMed Web of Science ®Google Scholar
• LARDER BA, DARBY G: Virus drug-resistance: mecha-nisms and consequences. Antiviral Res. (1984) 4:1–42.
   PubMed Web of Science ®Google Scholar
• DARBY G, FIELD HJ, SALISBURY SA: Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir resistance. Nature (1981) 289:81–83.
   PubMed Web of Science ®Google Scholar
• COTARELO M, CATALAN P, MENASALVAS C eta].: System-atic surveillance of herpes simplex virus (HSV) resis-tance to penciclovir (PCV), acyclovir (ACV) and foscarnet (FOS). 36th Intel-science Conference on Antimi-crobial Agents and Chemotherapy New Orleans (1996). Abstract H120.
   Google Scholar
• DARBY G: Acyclovir - and beyond J. InL Med. Res. (1994)22\(Suppl. 1):33A–42A.
   Google Scholar
• BURNETTE TC, HARRINGTON JA, REARDON JE et al.:Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug ofacyclovir.j Biol. Chem. (1995) 270:15827–15831.
   PubMed Web of Science ®Google Scholar
• DE MIRANDA P, BURNETTE TC, SMITH C et al.: Mecha-nisms of the enhanced oral bioavailability of acyclovir with the prodrug valaciclovir HC1 (Valtrex111). 34th In-terscience Conference on Antimicrobial Agents and Chemo-therapy Orlando (1994). Abstract 83.
   Google Scholar
• ROLAN P: Pharmacokinetics of new antiherpetic agents. Clin. Pharmacokinet. (1995) 29:333–340.
   PubMed Web of Science ®Google Scholar
• GLAXO-VVELLCOME: Valaciclovir prescribing information. US (1996).
   Google Scholar
• DE MIRANDA P, BLUM MR: Pharmacokinetics of acy-clovir after intravenous and oral administration. J. Antimicrob. Chemother. (1983) 12 (Suppl. B):29–37.
   Google Scholar
• LASKIN OL: Clinical pharmacokinetics of acyclovir. Clin.Pharmacokinet (1983) 8:187–201.
   PubMed Web of Science ®Google Scholar
• WANG LH, SCHULTZ M, WELLER S etal: Pharmacokinet-ics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic ther-apy. Antimicrob. Agents Chemother. (1996) 40:80–85.
   PubMed Web of Science ®Google Scholar
• GLAXO-VVELLCOME: Valaciclovir prescribing information. UK (1996).
   Google Scholar
• FIRST MR, BLUM MR, BRENNAN P eta].: Pharmacokinetics of 256U87, an acyclovir prodrug, in renal transplant patients [abstract]. Clin. Pharmacol Ther. (1993) 53:238.
   Google Scholar
• POSNER J, SOUL-LAWTON J, WELLER S eta].: Valtrex (Rm) (valaciclovir) - bioavailability in different patient popu-lations. Can. J. Infect. Dis. (1995) 6\(Suppl. 0:287C.
   Google Scholar
• JACOBSON MA, GALLANT J, WANG LH eta].: Phase I trialof valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob. Agents Chemother. (1994) 38:1534–1540.
   Google Scholar
• DE BONY F, BIDAULT R, PECK R eta].: Lack of interactionbetween valaciclovir, the L-valyl ester of aciclovir, and Maalox antacid. J. Antimicrob. Chemother. (1996) 37:383–387.
   Google Scholar
• SOUL-LAWTON J, CHAN PQ, POSNER J et al.: Lack ofinteraction between valaciclovir, the L-valyl ester of aciclovir, and digoxin. 7th International Congress for Infectious Diseases. Hong Kong (1996). Abstract 40.
   Google Scholar
• ROLAN PE, MAILLOT F, ON NT et al.: The effects ofcimetidine and probenecid on the conversion of a valine ester of acyclovir, 256U, to acyclovir and acy-clovir renal clearance in healthy volunteers. Br. J. Clin. Pharmacol. (1993) 35: Abstract 533P.
   Google Scholar
• DE BONY F, BIDAULT R, TOD M et al.: Interaction ofcimetidine and probenecid with valaciclovir and its metabolite acylovir. 36th Interscience Conference on An-timicrobial Agents and Chemotherapy. New Orleans (1996). Abstract A32.
   Google Scholar
• WHITLEY R, KROON S, WOOD M, SANDSTROM E: IHMFFocus. Guidelines and Recommendations from the Inaugu-ral Meeting of the International Herpes Management Forum. PPS Europe Ltd., Worthing (1993).
   Google Scholar
• WOOD MJ, BALFOUR H, BEUTNER K eta].: How should zoster trials be conducted? J. Antimicrob. Chem other. (1995) 36:1089–1101.
   PubMed Web of Science ®Google Scholar
• BEUTNER KR, FRIEDMAN DJ, FORSZPANIAKC et al.: Valaci-clovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimi-crob. Agents Chemother. (1995) 39:1546–1553.
   PubMed Web of Science ®Google Scholar
• JOHNSON RW, CROOKS RJ, AND THE INTERNATIONAL VALACICLOVIR ZOSTER STUDY GROUP: The clinical effi-cacy of valaciclovir in the treatment of herpes zoster. Eur. Acad. Dermatol Venereol (1995) 5\(Suppl. 1): Abstract 020.
   Google Scholar
• JOHNSON RW, SHUKLA S, FIDDIAN AP, CROOKS RJ: Im-portant covariates for predicting pain outcome in her-pes zoster. 8th World Congress on Pain. Vancouver (1996). Abstract 176.
   Google Scholar
• GOH CL, CROOKS RJ, SHUKLA S, AND THE VALACICLOVIR INTERNATIONAL ZOSTER ASSESSMENT GROUP: Valaci-clovir for the treatment of herpes zoster - influence of patient age and dermatome. 7th International Congress for Infectious Diseases. Hong Kong (1996). Abstract 95.010.
   Google Scholar
• CROOKS RJ, FIDDIAN AP, SHUKLA S: Analysis of post-her - petic neuralgia by intent-to-treat. 8th World Congress on Pain. Vancouver (1996). Abstract 165.
   Google Scholar
• GLAXO-WELLCOME: Personal communication (1996).
   Google Scholar
• HOPE-SIMPSON RE: The nature of herpes zoster: a long-term study and a new hypothesis. Proc. Roy. Soc. Med. (1965) 58:1–12.
   PubMedGoogle Scholar
• BURGOON CF, BURGOON JS, BALDRIDGE GD: The natu-ral history of herpes zoster. JAMA (1957) 164:265–269.
   PubMed Web of Science ®Google Scholar
• FIFE KH, AND THE INTERNATIONAL VALACICLOVIR HSV STUDY GROUP: Valaciclovir or acyclovir for the treat-ment of first episode genital herpes. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco (1995). Abstract H11.
   Google Scholar
• PATEL R, DELAHANTY J: Valaciclovir for the treatment of first episode genital herpes. 1st European Congress of Chemotherapy Glasgow (1996). Abstract W116.
   Google Scholar
• KINGHORN GI, FIDDIAN AP, AND THE INTERNATIONAL VALACICLOVIR HSV STUDY GROUP: Prevention of lesion development in recurrent genital herpes with oral valaciclovir. J. European Acad. Dermatol Venereol. (1995) 5 (Suppl. 1): Abstract S162.
   Google Scholar
• WOOLLEY P, CROOKS RJ, AND THE INTERNATIONAL VALACICLOVIR HSV STUDY GROUP: Prevention of ve-sicular lesions in recurrent genital herpes with oral valaciclovir. 1st European Congress of Chemotherapy Glas-gow (1996). Abstract W117.
   Google Scholar
• SPRUANCE SL, TYRING SK, DEREGORIO B et al.: A large-scale, phcebo-controlled, dose-ranging trial of per oral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch. Intern. Med. (1996) 156:1729–1735.
   PubMed Web of Science ®Google Scholar
• SMILEY ML, AND THE INTERNATIONAL VALACICLOVIR HSV STUDY GROUP: Valaciclovir and acyclovir for the treatment of recurrent genital herpes simplex virus infections. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993). Abstract 1210.
   Google Scholar
• SAIAG P, CHASTANG C, BERTIN I, AND THE GENIVALSTUDY GROUP: Efficacy and safety equivalence of 1000 mg once-daily and 500 mg twice-daily valaciclovir in recurrent genital herpes. 36th Intel-science Conference on Antimicrobial Agents and Chemotherapy. New Orleans (1996). Abstract H113.
   Google Scholar
• PATEL R, CROOKS RJ, BELL AR, AND THE EUROPEAN/AUS-TRALIAN VALACICLOVIR HSV STUDY GROUP: Once-daily valaciclovir for suppression of recurrent genital herpes - the first placebo-controlled clinical trial. 1st European Congress of Chemotherapy. Glasgow (1996). Abstract W115.
   Google Scholar
• PATEL R, CROOKS RJ, BELL AR et al.: Once daily valaci-clovir for suppression of genital herpes - results from two placebo-controlled studies. EUROGIN Conference on Herpes Viruses and Genital Pathology Paris (1996). Abstract.
   Google Scholar
• STERN J, DELEHANTY J, AND THE INTERNATIONAL VALACICLOVIR HSV STUDY GROUP: Once daily valaci-clovir for suppression of genital herpes - results from a large international study. 5th Western Pacific Congress on Chemotherapy and Infectious Diseases. Singapore (1996). Abstract - accepted for presentation.
   Google Scholar
• DRUCKER JL, MILLER JM, AND THE INTERNATIONAL VALACICLOVIR HSV STUDY GROUP: Once-daily valaci-clovir sustains the suppressive efficacy and safety re-cord of aciclovir in recurrent genital herpes. 1st European Congress of Chemotherapy Glasgow (1996) Ab-stract W118.
   Google Scholar
• MEYERS JD, FLOURNOY N, WADE JC et al.: Biology ofinterstitial pneumonia after marrow transplantation. In: Recent Advances in Bone Marrow Transplantation. Liss AR (Ed.), need Publishers, Country (1983):405–423.
   Google Scholar
• LJUNGMAN P, ENGELHARD D, LINK H et al.: Treatment ofinterstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immunoglobulin: experi-ence of European Bone Marrow Trans plant Group. Clin. Infect. Dis. (1992) 14:831–835.
   PubMed Web of Science ®Google Scholar
• JACOBSON MA, MILLS J: Serious cytomegalovirus diseasein the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis and treatment. Ann. Intern. Med. (1988) 108:585–594.
   PubMed Web of Science ®Google Scholar
• GALLANT JE, MOORE RD, RICHMAN DD et al.: Incidenceand natural history of cytomegalovirus disease in pa-tients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J. Infect. Dis. (1992) 166:1223–1227.
   Web of Science ®Google Scholar
• STUDIES OF OCULAR COMPLICATIONS OF AIDS RE-SEARCH GROUP IN COLLABORATION WITH THE AIDS CLINICAL TRIALS GROUP: Foscarnet-ganciclovir cy-tomegalovirus retinitis trial, IV: visual outcomes. Oph-thalmology (1994) 101:1250–1261.
   PubMed Web of Science ®Google Scholar
• MEYERS JD, REED EC, SHEPP DH et al.: Acyclovir forprevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. New Engl. J. Med. (1988) 318:70–75.
   PubMed Web of Science ®Google Scholar
• LEGENDRE C, DUCLOUX D, FERROUNI A et al: Acyclovirin preventing cytomegalovirus infection in kidney transplant recipients. J. Med. Virol. (1993) Suppl. 1:118–122.
   Google Scholar
• COOPER DA, PEHRSON PO, PEDERSON C et al.: The efficacy and safety of zidovudine alone or as co-therapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomised trial. AIDS (1993) 7:197–207.
   PubMed Web of Science ®Google Scholar
• YOULE MS, GAZZARD BG, JOHNSON MA et al.: Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a dou-ble-blind, placebo-controlled study. AIDS (1994) 8:641–649.
   PubMed Web of Science ®Google Scholar
• FEINBERG J, COOPER D: Phase III international study of valaciclovir (VACV) for cytomegalovirus (CMV) prophy-laxis in patients with advanced HIV disease. XI Interna-tional Conference on AIDS. Vancouver (1996). Abstract Th.B.300.
   Google Scholar
• CHULAY JD, BELL AR AND THE INTERNATIONAL VALACI-CLOVIR HSV STUDY GROUP: Long-term safety of valaci-clovir for suppression of herpes simplex virus infections [abstract]. Clin. Infect Dis. (1996) 23:879.
   Google Scholar
• REMUZZI G: HUS and TTP: variable expression of a single entity. Kidney Int. (1987) 32:292–308.
   PubMed Web of Science ®Google Scholar
• KELLEHER P, SEVERN A, THOMSON C et al.: The haemolytic uraemic syndrome in patients with AIDS. Genitourin. Med. (1996) 72:172–175.
   PubMedGoogle Scholar
• CROOKS RJ: Valaciclovir - a review of its potential in the management of genital herpes. Antiviral Chem. Chemother. (1995) 6:39–44.
   Web of Science ®Google Scholar